A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics

Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of developing treatment-emergent anti-drug antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Joanne, Lee, Stacey L., Russell, Anna M., Huang, Rong Fong, Batt, Micheal A., Chang, Shawn S., Ferrante, Andrea, Verdino, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301669/
https://www.ncbi.nlm.nih.gov/pubmed/34297759
http://dx.doi.org/10.1371/journal.pone.0254944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301669/
https://www.ncbi.nlm.nih.gov/pubmed/34297759
http://dx.doi.org/10.1371/journal.pone.0254944

Ejemplares similares